Mathias Locher

Medicine · Health Sciences

19h-index1.4kcitations46works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(16), Glycosylation and Glycoproteins Research(8), CAR-T cell therapy research(8), Analytical Chemistry and Chromatography(6), Biochemical Acid Research Studies(4)

Publications46 total

Monoclonal Antibodies: Discovery and Protein Engineering
2021
Biopharmaceuticals: CMC Development “Points to Consider” from a Regulatory Perspective
2021
Monoclonal Antibodies: Discovery and Protein Engineering
2021
Biopharmaceuticals: CMC Development “Points to Consider” from a Regulatory Perspective
2021· 3 cited
Characterization of Physicochemical Parameters in Toxicology
2021· 1 cited
Characterization of Physicochemical Parameters in Toxicology
2021· 1 cited
Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases
mAbs·2015· 90 citedOpen Access
Nonclinical safety testing of biopharmaceuticals – Addressing current challenges of these novel and emerging therapies
Regulatory Toxicology and Pharmacology·2015· 19 cited
New challenges and opportunities in nonclinical safety testing of biologics
Regulatory Toxicology and Pharmacology·2014· 26 cited
Characterization of Physicochemical Parameters in Toxicology
2014
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
Leukemia Research·2008· 79 citedOpen Access
Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class
Journal of Immunotherapy·2007· 188 cited
Activation of T Cells by Bispecific Single-Chain Construct MT103 (MEDI-538) Is Strictly Target Cell-Dependent.
Blood·2006
224 POSTER Characterization of a murine EpCAM/CD3-bispecific BiTE molecule as a surrogate for preclinical development of the human EpCAM/CD3-bispecific BiTE molecule MT110
European Journal of Cancer Supplements·2006
200 POSTER Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BITE class
European Journal of Cancer Supplements·2006
Effects of tryptophan supplementation on plasma tryptophan and related hormone levels in heifers and dairy cows
Domestic Animal Endocrinology·2006· 59 citedOpen Access
Exchanging human Fcγ1 with murine Fcγ2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model
Cancer Immunology Immunotherapy·2006· 14 citedOpen Access
A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients
European Journal of Cancer·2006· 55 cited
N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II
Metabolism·2006· 57 cited
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3
Cancer Immunology Immunotherapy·2005· 54 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Patrick A. Baeuerle(10), Klaus Brischwein(7), Peter Kufer(7), Harald O. Borbe(6), Bernd Schlereth(5), Róbert Hermann(5), Larissa Parr(4), Norbert Knebel(4), G Niebch(4), Sally Grieb(4), Robert Hofmeister(3), Sandra Lippold(3), Nadja Prang(3), Wibke Lembke(3), Bernd Schlereth(3), Grit Lorenczewski(3), Hartmut Derendorf(3), Michael Schwenk(3), Andreas Wolf(2), Ralf Lutterbuese(2)